Compound ID | 1186

Update compound information

Faropenem medoxomil

Class: Beta-lactam

Spectrum of activity: Gram-negative
Details of activity: Being developed for the treatment of community acquired pneumonia
Institute where first reported: Asubio Pharma
Year first mentioned: 1995
Highest developmental phase: Phase 3 (suspended)
Development status: Active
Chemical structure(s):
Click here for structure editor
Molecular weight: 397.4
Iso. SMILES: CC1=C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4
InChI Key: JQBKWZPHJOEQAO-DVPVEWDBSA-N
Can. SMILES: C[C@H]([C@H]1C(=O)N2C(=C([C@H]3CCCO3)S[C@H]12)C(=O)OCC4=C(C)OC(=O)O4)O
InChI: InChI=1S/C17H19NO8S/c1-7(19)11-14(20)18-12(13(27-15(11)18)9-4-3-5-23-9)16(21)24-6-10-8(2)25-17(22)26-10/h7,9,11,15,19H,3-6H2,1-2H3/t7-,9-,11+,15-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/6918218
Guide to Pharmacology: faropenem
Citation: https://journals.asm.org/doi/10.1128/aac.01566-08

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.